Context Therapeutics Inc. Common Stock
Symbol: CNTX (NASDAQ)
0.86
▲ (0.92%) 0.008
Company Description:
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Key Stats
- Today's Open: $0.85
- Today's High: $0.867
- Today's Low: $0.83
- Today's Volume: 17.62K
- Yesterday Close: $0.8502
- Yesterday High: $0.8849
- Yesterday Low: $0.83
- Yesterday Volume: 106.79K
- Last Min Volume: 700
- Last Min High: $0.858
- Last Min Low: $0.858
- Last Min VWAP: $0.858
Company Profile
- Name: Context Therapeutics Inc. Common Stock
- Website: https://www.contexttherapeutics.com
- Listed Date: 2021-10-20
- Location: PHILADELPHIA, PA
- Market Status: Active
- CIK Number: 0001842952
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $76.27M
- Round Lot: 100
- Outstanding Shares: 89.70M
- Asset Type: CS
RECENT FILINGS FOR CNTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-02 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-06 | 10-Q | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 3 | View |
| 2025-06-02 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-09 | SCHEDULE 13G/A | View |
Latest News on CNTX